Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Factors moderating the relative effectiveness of varenicline and nicotine replacement therapy in clients using smoking cessation services

Walker, Neil, Gainforth, Heather, Kiparoglou, Vasiliki, Robinson, Hayley, van Woerden, Hugo and West, Robert 2018. Factors moderating the relative effectiveness of varenicline and nicotine replacement therapy in clients using smoking cessation services. Addiction 113 (2) , pp. 313-324. 10.1111/add.14004

Full text not available from this repository.

Abstract

Aims To assess how far the greater effectiveness of varenicline over nicotine replacement therapy (NRT) is moderated by characteristics of the smokers or setting in clinical practice. Design We used observational data from 22,472 treatment episodes between 2013 and 2016 from smoking cessation services in England to assess whether differences between varenicline and NRT were moderated by a set of smoker and setting characteristics: these included level of social deprivation, age, gender, ethnic group, nicotine dependence, and treatment context. From the above, 15,640 episodes were analysed in relation to 4-week quit and 14,273 episodes at 12 weeks. All two-way interactions involving pharmacotherapy were fitted in addition to the main effects and a parsimonious model identified using a backwards stepwise selection procedure. Findings At both follow-up points, varenicline was associated with higher success rates overall (p<0.001 at both 4 and 12 weeks; adjusted odds ratio varenicline vs NRT = 1.82 [95%CI 1.61, 2.06] and 2.58 [95%CI 2.26, 2.94] at 4 and 12 weeks respectively). At 12 weeks, the relative benefits of varenicline were found to be influenced by the setting in which advice was provided (p<0.001 for interaction pharmacotherapy × setting; adjusted OR for varenicline × pharmacy setting = 0.53, [95% CI 0.42, 0.69] and for varenicline × General Practice setting = 0.79, [95% CI 0.64, 0.98] against a baseline of 1 for varenicline × community setting). The same trends were evident at 4 weeks but this did not translate to statistical significance. There was inconclusive evidence for moderating effects of other variables. Conclusions Varenicline use is associated with higher smoking cessation rates than nicotine replacement therapy in routine clinical practice, irrespective of a wide range of smoker characteristics, but the difference is less in certain intervention settings, most notably pharmacy but also GP practice, compared with community setting.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Wiley
ISSN: 0965-2140
Date of Acceptance: 7 August 2017
Last Modified: 06 Nov 2018 11:00
URI: http://orca.cf.ac.uk/id/eprint/116232

Citation Data

Cited 4 times in Google Scholar. View in Google Scholar

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item